 |
| 21-Mar-14 | Reiterated |
Barclays |
Equal Weight |
$115 → $130 |
|
| 31-Jan-14 | Reiterated |
Argus |
Buy |
$130 → $135 |
|
| 20-Nov-13 | Reiterated |
Deutsche Bank |
Buy |
$138 → $142 |
|
| 29-Aug-13 | Reiterated |
UBS |
Buy |
$121 → $124 |
|
| 27-Aug-13 | Reiterated |
Barclays |
Overweight |
$105 → $115 |
|
| 31-Jul-13 | Reiterated |
Oppenheimer |
Perform |
$100 → $109 |
|
| 24-Apr-13 | Reiterated |
Deutsche Bank |
Buy |
$108 → $115 |
|
| 15-Apr-13 | Reiterated |
Barclays |
Equal Weight |
$90 → $105 |
|
| 08-Apr-13 | Reiterated |
RBC Capital Mkts |
Outperform |
$95 → $105 |
|
| 25-Jan-13 | Upgrade |
Argus |
Hold → Buy |
$96 |
|
| 24-Jan-13 | Reiterated |
UBS |
Buy |
$96 → $98 |
|
| 12-Sep-12 | Downgrade |
Robert W. Baird |
Outperform → Neutral |
$84 |
|
| 10-Sep-12 | Upgrade |
UBS |
Neutral → Buy |
$80 → $96 |
|
| 02-Aug-12 | Downgrade |
Argus |
Buy → Hold |
|
|
| 15-Mar-12 | Resumed |
Stifel Nicolaus |
Hold |
|
|
| 09-Feb-12 | Downgrade |
Oppenheimer |
Outperform → Perform |
|
|
| 09-Sep-11 | Downgrade |
Standpoint Research |
Buy → Hold |
|
|
| 10-May-11 | Reiterated |
MP Advisors |
Outperform |
$63 → $65 |
|
| 25-Apr-11 | Reiterated |
Stifel Nicolaus |
Buy |
$70 → $68 |
|
| 21-Apr-11 | Reiterated |
Oppenheimer |
Outperform |
$66 → $63 |
|
|
|
| 17-Apr-14 05:03PM | FDA Grants Fast Track Status To Amgen Heart Failure Drug at Forbes |
| 04:10PM | Emergent BioSolutions Gains on Trial News Zacks |
| 04:05PM | Amgen Announces Webcast of 2014 First Quarter Financial Results PR Newswire |
| 02:34PM | A Real Dividend Growth Machine: Q1 2014 Review at Seeking Alpha |
| 01:22PM | [video] Kudlow: Two economic cycles at CNBC |
| 09:32AM | Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc. at Motley Fool |
| 16-Apr-14 03:10PM | Dynavax Starts Phase III Study on Heplisav-B Zacks |
| 05:00AM | 'Fast Money' Recap: Impressed by Yahoo! at TheStreet |
| 15-Apr-14 04:23PM | Nasdaq rides biggest trading rollercoaster in five years at CNBC |
| 04:20PM | Encouraging Results from Lexicon Candidate Zacks |
| 02:03PM | Capitulation or correction? Nasdaq nears 10% drop at CNBC |
| 01:19PM | Another Earnings Beat from J&J, View Up Zacks |
| 12:40PM | [video] Love biotech on correction: Trader at CNBC |
| 12:37PM | [video] Top biotech analyst forecasts bottom at CNBC |
| 06:49AM | Ambit Biosciences Slumps: AMBI Falls 13.0% in Session Zacks |
| 05:00AM | 'Fast Money' Recap: Long on Financials at TheStreet |
| 14-Apr-14 06:14PM | Amgen's Conundrum at Motley Fool |
| 03:30PM | Positive Results on Intercept Pharma's OCA Zacks |
| 10:30AM | Gilead Bucks Biotech Trend Thanks to Sovaldi News Zacks |
| 10:05AM | Momentum Investing: When Leaders Become Laggards at Barrons.com |
| 07:43AM | [video] Pro picks Gannett, Amgen & more at CNBC |
| 12-Apr-14 12:01AM | [$$] The Highfliers Are Still Too High at Barrons.com |
| 11-Apr-14 02:32PM | Are Celgene and Amgen Undervalued By the Market? at Motley Fool |
| 08:42AM | [video] Here's what's pushing biotech lower: Expert at CNBC |
| 08:32AM | 3 Biotech Companies That Look To Be Good Buys After A Pullback at Seeking Alpha |
| 12:06AM | This is the make-or-break level for biotech Talking Numbers |
| 10-Apr-14 03:39PM | Gilead Announces Encouraging Sovaldi Data Zacks |
| 03:37PM | Biotech: Like Lambs to the Slaughter at Barrons.com |
| 03:03PM | 'Very Volatile' Biotech, in Chart Form at The Wall Street Journal |
| 01:09PM | Oh Biotech, You Are a Cruel Bitch at TheStreet |
| 10:02AM | [video] Celgene CEO: Intellectual property is lifeblood of innovation at CNBC |
| 08:22AM | 3 Top-Ranked Biotech Stocks on the Rebound Zacks |
| 07:40AM | Moodys Levesque Says Heath Care Ratings at Risk (Audio) at Bloomberg |
| 09-Apr-14 05:30PM | Oncolytics Reports Additional Data on Reolysin Zacks |
| 10:50AM | Positive Trial Data Lifts Alkermes Zacks |
| 08-Apr-14 02:38PM | Amgen: Management's History Of Shareholder Friendliness at Seeking Alpha |
| 11:10AM | Halozyme Falls on Phase II Study Halt Zacks |
| 08:47AM | AMGEN INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 06:31AM | Zacks Rank #1 Additions for Tuesday Zacks |
| 07-Apr-14 05:43PM | [video] Biotech breakdown? at CNBC |
| 12:10PM | Amgen's Oncology Candidate Disappoints Zacks |
| 11:23AM | Pfizer Breast-Cancer Drug Scores, But Street Cautious at Investor's Business Daily |
| 04-Apr-14 10:28PM | The Biggest Dividends Arent Necessarily the Best at New York Times |
| 03:45PM | Glaxo and Amgen Terminate Agreement Zacks |
| 12:18PM | Midday movers: GrubHub, Amgen, Disney & more at CNBC |
| 11:33AM | Amgen melanoma drug fails to improve overall survival rates Reuters |
| 10:02AM | Amgen melanoma drug shrinks tumors but fails secondary study goal Reuters |
| 09:30AM | [$$] Amgen's Melanoma Treatment Study Disappoints at The Wall Street Journal |
| 09:00AM | Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma PR Newswire |
| 08:01AM | Zacks Rank #1 Additions for Friday Zacks |
| 03-Apr-14 08:43PM | Amgen, Inc. Pays GlaxoSmithKline plc (ADR) to Go Away at Motley Fool |
| 02:31PM | Does Amgen Have the Next Lipitor on Its Hands? at Motley Fool |
| 11:52AM | AMGN May 23rd Options Begin Trading at TheStreet |
| 11:12AM | Amgen, GSK End Marketing Partnership for Osteoporosis Drug at Fox Business |
| 10:50AM | Amgen Faces Cool Reception Over GSK Pact Termination 24/7 Wall St. |
| 09:58AM | Amgen ends marketing agreement with GSK for osteoporosis drug Reuters |
| 09:20AM | AMGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online |
| 02-Apr-14 03:37PM | Biotech Giants Now Priced Like Old World Drug Stocks at 24/7 Wall St. |
| 02:03PM | Gilead Sciences: What If Sovaldi Sales Peak Quickly, Fall Fast? at Barrons.com |
| 11:16AM | Entia: An Iron-Clad Opportunity in a Billion Dollar Market Accesswire |
| 01-Apr-14 04:09PM | Stocks rise as US manufacturing recovers AP |
| 02:31PM | Can This Drive Growth for Amarin Corporation plc? at Motley Fool |
| 01:03PM | 3 Stocks Driving The Drugs Industry Higher at TheStreet |
| 12:54PM | Health care stocks are outperforming; consider these picks from analyst Les Funtleyder Breakout |
| 11:52AM | Stocks rise as US manufacturing recovers AP |
| 05:57AM | [$$] Three Reasons to Be Cautious on Pfizer at Barrons.com |
| 31-Mar-14 03:20PM | Todays Top Biotech Stories: Curis, Amgen, and Novartis at Motley Fool |
| 03:03PM | Finding a Niche for Celgene's Otezla at Motley Fool |
| 03:00PM | [video] 3 to Watch: AMGN, TEVA & GM at CNBC |
| 02:51PM | [video] Injectable cholesterol drugs to face challenges at CNBC |
| 01:59PM | Amgen Stock Gets Bump Up On Cholesterol Drug Data at Investor's Business Daily |
| 01:19PM | [video] New class of cholesterol drugs at CNBC |
| 12:18PM | Midday Movers: Amgen, Biogen, Priceline & More at CNBC |
| 11:41AM | Amgen's Good News Bad News for Regeneron? at Barrons.com |
| 10:31AM | Amgen: Allowing Dividend Growth Investors To Capitalize On The Biotech Sell-Off at Seeking Alpha |
| 10:06AM | Stocks extend gains amid Fed Chair Yellen remarks; Dow spikes 150 at CNBC |
| 09:23AM | Morning Movers: Biogen Jumps on FDA Approval; Big Lots Gains on Upgrade at Barrons.com |
| 07:42AM | Amgen, McDermott International, Bank of America, Wells Fargo and McGraw Hill Financial highlighted as Zacks Bull and Bear of the Day Zacks |
| 07:00AM | Amgen Drug Cuts Cholesterol Levels In Pivotal Studies at TheStreet |
| 01:00AM | Bull of the Day: Amgen (AMGN) Zacks |
| 30-Mar-14 08:00AM | Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins PR Newswire |
| 29-Mar-14 05:10PM | Amgen Drug Slashes Bad Cholesterol Within Weeks of Treatment Bloomberg |
| 05:10PM | Amgen Drug Slashes Bad Cholesterol Within Weeks of Treatment at Bloomberg |
| 02:00PM | New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol PR Newswire |
| 02:00PM | Amgen drug lowers cholesterol up to 66 pct in pivotal studies Reuters |
| 28-Mar-14 05:50PM | Biotech: Past Performance Doesn't Predict the Future at Barrons.com |
| 11:00AM | Aegerion Pharmaceuticals Viability Threatened As Regulatory, Legal And Market Forces Close In at Seeking Alpha |
| 07:39AM | Cytokinetics announces opening to enrollment of COSMIC-HF expansion theflyonthewall.com |
| 05:00AM | 'Fast Money' Recap: Downward Pressure at TheStreet |
| 27-Mar-14 05:36PM | [video] Biotech: Buy the dip? at CNBC |
| 04:39PM | House approves bill to stop cut to Medicare docs AP |
| 11:13AM | Amgen: Overlooked, Worth Buying, Morgan Stanley Says at Barrons.com |
| 10:39AM | Amgen - On Course To Change The Future at Seeking Alpha |
| 08:55AM | Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks at 24/7 Wall St. |
| 26-Mar-14 06:31PM | Is Idera's Sell-Off Premature? at Motley Fool |
| 06:26PM | Merck, Glaxo end co-pay assistance for Obamacare plans Reuters |
| 04:48PM | [$$] Biotech Stocks Break Down, a Bad Omen at Barrons.com |
| 04:18PM | Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session PR Newswire |
| 04:10PM | [$$] Biotech Stocks Break Down, a Bad Omen at Barrons.com |
| 08:16AM | The Zacks Analyst Blog Highlights: IShares NASDAQ Biotechnology ETF, Gilead, Alexion Pharmaceuticals, Amgen and Myriad Genetics Zacks |
|
|
| Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| de Carbonnel Francois | Director | Mar 06 | Option Exercise | 54.44 | 10,000 | 544,350 | 25,364 | Mar 07 05:23 PM | | de Carbonnel Francois | Director | Mar 06 | Sale | 126.69 | 1,000 | 126,690 | 18,343 | Mar 07 05:23 PM | | BALTIMORE DAVID | Director | Feb 26 | Option Exercise | 62.55 | 5,000 | 312,750 | 31,879 | Feb 26 08:28 PM | | HENDERSON REBECCA M | Director | Feb 13 | Option Exercise | 62.41 | 20,000 | 1,248,160 | 25,549 | Feb 14 04:34 PM | | HENDERSON REBECCA M | Director | Feb 13 | Sale | 123.53 | 20,000 | 2,470,680 | 5,549 | Feb 14 04:34 PM | | Bradway Robert A | Chairman, CEO and President | Feb 12 | Option Exercise | 62.55 | 65,000 | 4,065,750 | 216,040 | Feb 14 04:19 PM | | AMGEN INC | 10% Owner | Dec 17 | Buy | 7.00 | 272,142 | 1,904,994 | 541,399 | Dec 18 06:09 PM | | Balachandran Madhavan | EVP, Operations | Sep 04 | Option Exercise | 58.43 | 18,000 | 1,051,740 | 59,133 | Sep 05 07:33 PM | | Balachandran Madhavan | EVP, Operations | Sep 04 | Sale | 112.76 | 18,000 | 2,029,768 | 34,851 | Sep 05 07:33 PM | | BALTIMORE DAVID | Director | Aug 28 | Sale | 109.66 | 4,582 | 502,462 | 27,789 | Aug 30 05:36 PM | | Amgen Ventures LLC | 10% Owner | Jun 05 | Buy | 15.00 | 16,666 | 249,990 | 334,126 | Jun 05 04:01 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 22 | Option Exercise | 54.62 | 6,130 | 334,791 | 22,863 | May 24 05:18 PM | | Dittrich Thomas J.W. | VP, Finance & CAO | May 22 | Sale | 104.78 | 6,130 | 642,296 | 16,733 | May 24 05:18 PM | | Balachandran Madhavan | EVP, Operations | May 21 | Option Exercise | 50.44 | 6,000 | 302,640 | 46,956 | May 21 08:18 PM | | Balachandran Madhavan | EVP, Operations | May 21 | Sale | 103.28 | 6,000 | 619,681 | 34,851 | May 21 08:18 PM | | HENDERSON REBECCA M | Director | May 17 | Option Exercise | 55.76 | 7,000 | 390,310 | 13,898 | May 20 07:15 PM | | HENDERSON REBECCA M | Director | May 17 | Sale | 105.72 | 8,421 | 890,300 | 5,477 | May 20 07:15 PM | | Patton Cynthia M | SVP & CCO | May 16 | Option Exercise | 54.58 | 3,544 | 193,437 | 18,986 | May 17 05:42 PM | | Patton Cynthia M | SVP & CCO | May 16 | Sale | 105.01 | 3,544 | 372,148 | 15,442 | May 17 05:42 PM | | BIONDI FRANK | Director | May 14 | Option Exercise | 56.50 | 10,000 | 564,950 | 39,780 | May 16 05:38 PM | | PELHAM JUDITH C | Director | May 14 | Option Exercise | 55.47 | 25,000 | 1,386,650 | 48,149 | May 16 05:42 PM | | BIONDI FRANK | Director | May 14 | Sale | 108.43 | 10,000 | 1,084,318 | 29,780 | May 16 05:38 PM | | PELHAM JUDITH C | Director | May 14 | Sale | 108.25 | 25,000 | 2,706,165 | 23,149 | May 16 05:42 PM | | de Carbonnel Francois | Director | Apr 30 | Option Exercise | 54.74 | 10,000 | 547,400 | 21,930 | May 02 06:26 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 29 | Option Exercise | 50.44 | 10,000 | 504,400 | 64,643 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 29 | Sale | 107.02 | 10,000 | 1,070,191 | 54,643 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 26 | Option Exercise | 58.43 | 10,000 | 584,300 | 66,077 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 26 | Sale | 107.99 | 10,000 | 1,079,872 | 56,077 | Apr 30 05:21 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 25 | Option Exercise | 54.69 | 8,662 | 473,725 | 65,973 | Apr 26 05:33 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 25 | Sale | 107.95 | 8,662 | 935,029 | 57,311 | Apr 26 05:33 PM | | MCNAMEE BRIAN M | SVP, Human Resources | Apr 24 | Sale | 105.95 | 6,924 | 733,565 | 58,311 | Apr 26 05:33 PM |
|
|
|
|
|
|
